Novamind Inc.'s Profile

Top Members

Novamind Inc.'s Bulletin

TORONTO, ON / June 17, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that it has made a strategic investment of US$1,000,000 (the "Strategic Investment") in a stealth mode drug development company based in the United States (the "Investee"). The Investee operates a drug discovery and development business focused on neuropsychiatric disorders. Novamind's Strategic Investment represents a minority equity investment in the Investee, part of a Series A financing led by Apeiron Investment Group pursuant to which the Investee raised aggregate gross proceeds of US$25,000,000. The Strategic Investment leverages Novamind's expertise in patient recruitment and patient management for the Investee's development of novel treatments for neuropsychiatric disorders. Novamind expects to share further details relating to the Strategic Investment as they become available when confidentiality restrictions are lifted. About NovamindNovamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Contact InformationNovamindYaron Conforti, CEO and DirectorTelephone: +1 (647) 953 9512 Bill Mitoulas, Investor RelationsEmail: bill@novamind.ca Forward-Looking Statements This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws. SOURCE: Novamind Inc.
The 10 Most Important Health Breakthroughs You Missed During the Pandemic While most eyes were on COVID-19, researchers have also made groundbreaking advancements in other fields. Here’s a look. Psilocybin and MDMA prove their psychotherapeutic mettle Psilocybin and MDMA prove their psychotherapeutic mettle Todd Detwiler for TIME Over the past year, psychoactives that had been mostly used as recreational drugs started really establishing themselves as frontline mental-health treatments. In an April study, published in the New England Journal of Medicine, 59 patients with depression were divided into two groups: one received psilocybin (a.k.a. psychedelic mushrooms); the other received escitalopram (a selective serotonin reuptake inhibitor and a smaller dose of psilocybin). Both had therapy alongside the treatment. At the end of the six-week study period, those in the psilocybin group performed better on a self-rating depression survey than those receiving the escitalopram—though the difference was just shy of statistical significance. In an unrelated Nature Medicine study published in May, 90 people suffering from PTSD were similarly divided into two groups, one of which received three doses of MDMA—the active ingredient in ecstacy—plus talk therapy. The other received the therapy and a placebo. The conclusion: 67% of the people who had taken MDMA no longer met the criteria for a PTSD diagnosis, compared with 32% of the placebo group. Multiple startups—including Canada-based Cybin and U.K.-based Compass Pathways—are working to commercialize the use of psychoactives for therapeutic purposes. The other big vaccine news Public-health officials have long sought a vaccine against malaria, which infects up to 600 million people a year and kills 400,000, mostly children. This year, there was dramatic prog­ress toward that goal. In a study of 450 children in Burkina Faso, published in the Lancet in April, researchers reported that a new malaria vaccine, called R21, is 77% effective—just clearing the World Health Organization’s 75% efficacy standard. However, the sample group was comparatively small, and while the subjects were followed for 12 months, malaria is active in Burkina Faso for only about six months out of the year, making it unclear if the disease’s half-year absence was partly responsible for the study’s promising results. Investigators working for a multicenter international team including the University of Oxford plan to follow the initial sample group for at least another year and will conduct other trials in countries where malaria is active year-round, while also working to improve the shot so it triggers a more effective immune response. New face, new hands—new man Todd Detwiler for TIME In summer 2020, a team of 16 surgeons and 80 operating-room staffers at NYU Langone Health performed the world’s first successful face and double hand transplant, completing the procedure in just 23 hours. Speed is essential in transplant surgery, because the sooner donor tissue is connected to the recipient’s vascular system, the less time it is denied a blood supply. The recipient was 22-year-old Joe DiMeo of Clark, N.J., who suffered third-degree burns over 80% of his body in a 2018 car accident. His finger­tips had to be amputated, and damage to his face was so extensive that he was left without lips or eyelids—even after 20 reconstructive surgeries. In 2019, DiMeo was listed as a possible transplant recipient; 10 months later, a suitable face-and-hands donor was located. Only two other face-and-hand transplants have been attempted: in the first, the recipient died of complications from the surgery; in the second, the hands had to be amputated because of infection. Advanced computer modeling helped the surgeons plan the latest transplant, and 3-D cutting guides assisted in sawing and aligning bones, as well as properly position the plates used to attach the donor tissue. More than nine months postsurgery, DiMeo continues to recover—and thrive. An obesity drug that actually works A study published in March in the New England Journal of Medicine showed that the drug semaglutide—typically administered to treat Type 2 diabetes—can have powerful weight-loss effects. A sample group of 1,961 people with a body mass index of 30 or greater (the level considered “obese,” though the scale has been criticized for overgeneralizing) were given either a weekly dose of 2.4 mg of semaglutide (the average weekly dose for diabetes treatment is 1 mg) or a placebo, coupled with lifestyle intervention like diet and exercise. At the end of a 68-week trial period, the semaglutide group lost an average of 14.9% of their body weight compared with 2.4% for the placebo group. A clear connection between sleep and dementia A clear connection between sleep and dementia Todd Detwiler for TIME Poor sleep duration has long been thought to be associated with Alzheimer’s disease and other neurodegenerative conditions, but the cause-and-effect asciation is hard to establish, and studies typically don’t run past 10 years or so, making it hard to track how sleep patterns play out over decades. In a robust study published in April in Nature Communications, a sample group of 7,959 people had their health and sleep patterns tracked throughout their 50s, 60s and 70s. The results were striking: those who slept six hours or less per night had a 30% higher risk of developing dementia than those who slept seven hours. While depression and other mental-health disorders are thought to have a role in changes in sleep duration and increasing dementia risks, the investigators corrected for those variables and did not find them to be relevant in their findings. They also ruled out sociodemographic and cardiometabolic factors. Though the investigators did not say with certainty which mechanism connects short sleep cycles to the onset of dementia, they speculated that lack of sufficient sleep can be associated with neuroinflammation, atherosclerosis and poor clearance of amyloid protein—which makes up Alz­heimer’s plaques—from the body. Polio kicked out of Africa As recently as the 1990s, an estimated 75,000 children in Africa were paralyzed by polio each year. Last year, Nigeria—the last country on the continent to have reported a case of wild polio—was declared clear of the disease, making Africa as a whole polio-free. The breakthrough was a result of the Kick Polio Out of Africa campaign launched in 1996 by Rotary International in collaboration with groups including UNICEF, the World Health Organization, the U.S. Centers for Disease Control and Prevention, and others. Polio, which in 1988 was endemic in 125 countries around the world, has now been eliminated in all but just two of them: Afghanistan, where there were 56 cases of wild polio in 2020; and Pakistan, where there were 84. The first human-monkey chimera In an April study published in the journal Cell, professor Juan Carlos Izpisua Belmonte created an embryonic chimera that combined human and nonhuman primate cells, designed for research purposes only, and unable to advance beyond the embryonic stage. The research has two purposes. The first is to study the process known as gastrulation—the point two weeks after conception when embryonic cells begin to differentiate into the body’s more than 200 cell types. The second goal is to help scientists develop better systems for growing tissues and organs—intended for transplantation into humans—in other animals, including pig embryos, which are less ethically controversial and more accessible. A gut check on Alzheimer’s risk A gut check on Alzheimer’s risk Todd Detwiler for TIME It’s no secret that the human microbiome has a profound effect on overall health. Now research has gone further than ever before to establish that the trillions of bacteria and other microorganisms that live in the gut play a role in one of the most devastating illnesses of all: Alzheimer’s disease. In a study led by researchers at the Istituto Centro San Giovanni di Dio Fatebenefratelli in Italy, investigators looked at lipopolysaccharides, proteins on the membranes of gut bacteria that cause inflammation, as well as at certain short-chain fatty acids, some of which have neuroprotective effects. Using PET scans and blood tests of 89 people ages 65 to 85, the researchers found a higher incidence of amyloid plaques in the brains of those with higher levels of lipopolysaccharides and the bad fatty acids in their blood—and thus in their gut bacteria. Fewer plaques were found in those with the protective fatty acids. The findings point to the possibility of microbiota manipulation as a preventive for Alzheimer’s. Bone-marrow transplant cures HIV  For blood-cancer patients who are not responding to chemotherapy, a bone-marrow transplant is sometimes an option. For one such patient in the U.K., the transplant proved to be a treatment for a second disease, too: HIV/AIDS. The patient received marrow from a donor who had a mutation in the CCR5 gene, which prevents HIV from effectively binding to cells. After the transplant, circulating HIV disappeared from the formerly positive patient’s blood. What’s more, 18 months after the patient stopped using antiretroviral medications, the virus had not yet reappeared. However, the doctors involved stress that such transplants can carry more risk than simply staying on retroviral medications. Stopping dengue at the source Stopping dengue at the source Todd Detwiler for TIME Dengue fever has had a free ride for too long. There is no effective vaccine or therapeutic against the mosquito-borne disease, which infects 50 million people per year—and in a warming planet, the dengue-carrying Aedes aegypti mosquitoes’ range is spreading to include regions that typically had a low incidence of the disease. But a study led by the World Mosquito Program in the Indonesian city of Yogyakarta and released in August 2020 may point to a solution: infect the insects with another pathogen—the Wolbachia bacterium—which prevents Aedes aegypti from spreading dengue when they bite humans. In the 27-month trial, Wolbachia-infected mosquitoes were released across Yogyakarta, and the result was a 77% reduction in dengue incidence. The benefits of the strategy can be self-sustaining, because Wolbachia-infected mosquitoes can spread the bacterium via their eggs when they reproduce. Investigators believe the strategy may also be effective in preventing other mosquito-borne viral diseases, including Zika, chikungunya and yellow fever. Source: https://time.com/6071578/health-breakthroughs-covid-19/?amp=true&__twitter_impression=true
Novamind to be featured in panel discussions on the disruptive potential of psychedelic treatments TORONTO, ON / ACCESSWIRE / June 15, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference (the "Conference"), taking place virtually on Thursday, June 17th, 2021. Novamind's CEO and Director, Yaron Conforti, will present the Company's vision for rapidly scaling access to psychedelic medicine through its network of specialized psychiatry clinics, and will describe its research partnerships with prominent pharmaceutical companies and academic institutions. The corporate presentation will be available to registered Conference attendees for on-demand viewing beginning at 7:00 AM EST on June 17th. Novamind will participate in two panels: Mr. Conforti will appear in a panel titled Disruptive Psychopharmacology - An Introduction to Psychedelics and the Coming Revolution in Psychiatry at 9:00 AM EST Novamind's Chief Medical Officer, Dr. Reid Robison, will appear on a separate panel titled Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry at 2:00 PM EST "Novamind has over five years of operational expertise with psychedelic medicine, a track record of innovative treatment protocol development, and strong clinical research partnerships with blue-chip pharmaceutical companies," said Mr. Conforti. "I'm excited to share our vision for the next chapter of mental health treatment at the Conference." Qualified investors can learn more about the H.C. Wainwright conference and register to schedule a one-on-one meeting with Novamind's management here. About Novamind Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. About H.C. Wainwright & Co. H.C. Wainwright is a full service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales & trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information, visit H.C. Wainwright & Co. on the web at www.hcwco.com CONTACT:NovamindYaron Conforti, CEO and DirectorTelephone: +1 (647) 953 9512Bill Mitoulas, Investor RelationsEmail: bill@novamind.ca Forward-Looking Statements This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws. SOURCE: Novamind Inc.
  A weekly summary of Novamind news and media, including the announcement of a new psychedelic therapy protocol for frontline healthcare workers.         FEATURES  June 7, 2021 A Quarter of Growth Green Market Report covers our fiscal Q3 earnings in their Psychedellux recap of the top business stories in the psychedelic medicine industry. Novamind reported total revenue of $1.8 million, a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics.   View all media       Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers “Together with the Wholeness Center, we’re joining forces to offer a new therapy that will positively impact the people who show up every day and continue to provide critical healthcare for the public during—and after—this difficult time,” said Dr. Robison. Click here to learn more about the Frontline KAP protocol June 10, 2021   View all press releases       The Brain-Changing Magic of New Experiences From GQ's series on mental health comes a piece about the psychological reasons how new experiences can change how we perceive time and make us more resilient. It's an interesting read and the author even compares trees blooming in spring to psychedelics. "Even the most mundane new experiences left me feeling genuinely elated." There's a reason for it too. From Dr. Laurie Santos, “Novel stimuli tend to activate regions of our brain that are associated with rewards.” At our Cedar Psychiatry clinics, we practice a holistic approach to mental health. Taking into account psychological, biological, social, environmental, and cultural influences. Learn more here.   Atai Life Sciences Announces Launch of Initial Public Offering We’ve always believed in Atai’s vision to transform the treatment of mental health disorders. It’s why we became early strategic investment partners. Congratulations to Atai Life Sciences on launching their initial public offering.          Follow @novamind_inc on Instagram               For further information, contact: Bill MitoulasInvestor Relations Telephone: +1 (416) 479 9547 Email: bill@novamind.ca